1Johnson DA, Stacy T, Ryan M, et al. A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 2005, 22 : 129-134.
2Hunt RH, Amstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol, 2005,100: 1949-1956.
3Shimatani T, Inoue M, Kuroiwa T, et al. Acid-suppressive efficacy of a reduced dosage of rabeprazole:comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry. Dig Dis Sci, 2005, 50: 1202-1206.
5Katz PO, Castell DO, Chen Y, et al. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study. Aliment Pharmacol Ther, 2004, 20:399-406.
6Wider-Smith C, Lind T, Lundin C, et al. Acid control with esomeprazole and lansoprazole:a comparative dose-response study. Scand J Gastroenterol, 2007, 42: 157-164.
7Metz DC, Ferron GM, Panl J, et al. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study. J Clin Pharmacol, 2002, 42:512-519.
9Tutuian R, Katz PO, Castell DO, et al. Noclurnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol, 2004, 16: 441-443.
10Kuo B, Castell DO. Optimal dosing of omeprazole 40mg daily: effects on gagtric and esophageal pH and serum gastrin in healthy corntrols. Am J Gastroenterol, 1996, 91: 1532- 1538.
3Frootan M, Choobtashani S, Azargashb E, et al. Non -erosive reflux disease compared with erosive esophagitis with regards to acid reflux and symptom patterns [ J ]. Turk J Gastroenterol, 2011 , 22(5) : 464.
